IIVS, Advancing Science & Animal Welfare Together

Introducing a New Photoreactivity Assay

IIVS is excited to announce the successful transfer of the Reactive Oxygen Species (ROS) photoreactivity assay into our laboratory. This high-throughput, in chemico screening assay, adopted as OECD Test Guideline 495, is designed to assess photoreactivity potential of test substances through measurement of two ROS: singlet oxygen (SO) and superoxide anion (SA).


Two reaction mixtures are prepared for each test substance to detect the generation of SO and SA produced through the bleaching of p-nitrosodimethylaniline (RNO) and the reduction of nitroblue tetrazolium (NBT), respectively. After exposure to simulated sunlight, which includes UVB, UVA, and visible light, the amount of ROS generated is determined. Photoreactive test substances have the potential to become more reactive and/or more toxic upon exposure to irradiation, and often require further evaluation in other photosafety assays. The photo-ROS assay is presented in the ICH S10 Photosafety document (2015), the OECD Phototoxicity IATA (2024), and recent manuscripts evaluating phototoxicity and photoallergy. After the evaluation of 17 proficiency chemicals, IIVS is pleased to now offer this assay commercially under full GLP compliance.

We will be presenting our work to transfer and optimize this assay at the annual Society of Toxicology (SOT) meeting in Orlando during the poster session on March 19th. Stop by our booth (1041) or look out for our photo program lead Allison Hilberer at our poster:

Transfer and Refinement of the Reactive Oxygen Species (ROS) Assay to Evaluate Photoreactivity Potential. 

photo of ROS reaction mixtures curtesy of IIVS

Photo Of ROS reaction Mixtures Curtesy of IIVS

Visit us during ToxExpo at SOT

Booth #1041

IIVS Validation Services


Image Created in CoPilot

We have witnessed how the validation process for NAMs has been steadily evolving since our founding of IIVS in 1997. At that time, validation bodies provided funding and oversite for large multi-laboratory efforts. Pre-validations were often used as a way to verify transferability of the method on a small scale to optimize and further refine the protocol, leading to greater success in larger validation studies. Then, as method developers have had to take on more of the financial burden to conduct and manage their validation efforts, they turned to ring trials to conduct their validations more quickly than the traditional pathway, sometimes with less than ideal outcomes. Now, OECD Guidance Document 34 on how to conduct validations is under review to improve and speed up the process of validations. Method developers are motivated to move their methods through the validation process themselves, whether this validation is ultimately intended to result in a test guideline for regulatory use, or if they simply want an assessment of the relevance and reliability of their method, but they may need additional support and expertise to navigate the numerous challenges in the validation process.



IIVS has participated in dozens of validations in our laboratories following both the original validation procedures and ring trials. We have experience serving as a participating laboratory, lead laboratory, member of the validation management team, peer reviewer, validation report author, and validation report and data auditor. No matter the validation paradigm, our experience in technology transfer, chemical selection, data governance, and protocol optimization is valuable to the field. The mission at IIVS is to increase the use and acceptance of non-animal testing worldwide. To further support this mission, we are offering our validation experience as a consulting service to help as many method developers as possible reach successful validation outcomes. If you would like to partner with us to provide these services or you would be interested in exploring how you could use our validation services, reach out to us via email at clientservices@iivs.org or plan to drop by our SOT booth (#1041) to talk to us. We are excited about formalizing this offering and hope to help bring your methods through the validation process successfully. 

Please join a workshop we are hosting and co-organizing with VITROCELL and Alveolix which will offer expert lectures, laboratory demonstrations and hands-on exercises related to the assessment of aerosols at the air-liquid interface.


June 26-27, 2025

IIVS Headquarters

Gaithersburg, MD

Find out more and Register

Recent Publications

A Proof-of-Concept for Safety Evaluation of Inhalation Exposure to Known Respiratory Irritants Using In Vitro and In Silico Methods


Optimizations of the Reconstructed Human Epidermis-Based Phototoxicity Testing to Evaluate the Safety of Long-Lasting Cosmetic Products

Quality Assurance for NAMs






GLP 302: half day in person course in conjunction with the Society of Quality Assurance meeting.

To meet the needs of the changing landscape, quality assurance (QA) professionals will need to expand their skills to properly audit these methods not only within the context of regulatory studies, but also prior to regulatory use, when the focus of the work must be on establishing the credibility and reliability of NAMs for use in regulated studies. This continuing education course is designed to introduce QA professionals to the principles and practices described in OECD guidance document 286: Good In Vitro Method Practices (GIVIMP).The GIVIMP guidance provides a supplement to good laboratory practice(GLP) regulations that QA professionals can refer to when preparing to audit NAMs. GIVIMP principles also support NAM method development, with guidance intended to ensure that NAMs are based on strong science.

Last week Kristie Sullivan presented with other colleagues in a session on redefining acute toxicity testing to embrace non-animal approaches at the ToxForum winter meeting in Raleigh, NC.


Her presentation detailed the status of alternatives for various acute toxicity endpoints and dug into solutions for skin irritation, especially for pesticide formulations.


To learn more about IIVS capabilities for skin irritation assessment in vitro, visit our web site.

From left to right: Joseph Henriquez, Corteva Agriscience; Colin North, BASF; Kristie Sullivan, IIVS; Tiffany Zapata, Syngenta; Agnes Karmaus, Syngenta; Amber Daniel, Inotiv.

We want to hear from you
IIVS is always interested in the needs and requests from researchers interested in advancing the awareness, acceptance and use of alternative methods. If you have any input on methodologies of interest, please don't hesitate to contact us at clientservices@iivs.org.
Connect With Us
Linkedin  Youtube